General
Preferred name
NALIDIXIC ACID
Synonyms
Nalidixic acid sodium ()
NSC-82174 ()
Baktogram ()
Sodium nalidixate ()
Nalidixic acid sodium salt hydrate ()
Nalidixic acid sodium salt ()
Nalidixic acid ()
Nalidixic acid (sodium salt) ()
NALIDIXATE SODIUM ()
WIN 18,320 ()
Mictral ()
Acido nalidixico ()
Nalidixane ()
Uroneg ()
Neggram ()
Acide nalidixique ()
WIN-18320 ()
Negram ()
Uriben ()
Neg Gram ()
Nalix ()
Nalidixate ()
Nalidixate sodium anhydrous ()
WIN-18320-3 ()
WIN 18,320-3 ()
Nalidixate sodium monohydrate ()
P&D ID
PD001597
CAS
389-08-2
3374-05-8
15769-77-4
Tags
available
drug
drug candidate
Approved by
FDA
First approval
1964
Drug indication
Urinary tract infection
osteomyelitis
Drug Status
approved
withdrawn
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE
Following oral administration, NegGram is rapidly absorbed from the gastrointestinal tract, partially metabolized in the liver, and rapidly excreted through the kidneys.; Approximately four percent of NegGram is excreted in the feces.
DESCRIPTION
Nalidixic acid is a 1,8-naphthyridine derivative belonging to the quinolone class of antibacterial compounds, with activity against Gram-negative bacteria .
(GtoPdb)
DESCRIPTION
Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria[1].
PRICE
29
PRICE
29
DESCRIPTION
Nalidixic acid was the first quinolone-based antibiotic. It is effective against both gram-positive and gram-negative bacteria. It inhibits DNA gyrase and topoisomerase IV activity in Gram-negative bacteria. Nalidixic acid is used for the treatment of urinary tract infections.
(Enamine Bioactive Compounds)
DESCRIPTION
Nalidixic acid (NSC-82174) is a synthetic 1, 8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA GYRASE.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Inhibits bacterial DNA polymerase (DNA gyrase)
(LOPAC library)
DESCRIPTION
Nalidixic acid sodium salt (Baktogram) is an antimicrobial agent with a limited bacteriocidal spectrum.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
27
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
NIH Clinical Collections (NCC)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
70
Molecular Weight
232.08
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
2
cLogP
1.42
TPSA
72.19
Fraction CSP3
0.25
Chiral centers
0.0
Largest ring
6.0
QED
0.85
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
DNA Gyrase
Target
antibiotic
Bacterial
Topo II
Topoisomerase
Selection Antibiotics for Transfected Cell,Topoisomerase
Indication
urinary tract infections
MOA
bacterial DNA gyrase inhibitor
ATC
J01MB02
Pathway
DNA Damage/DNA Repair
Microbiology/virology
Anti-infection
Cell Cycle/DNA Damage
Therapeutic Class
Antibiotics
Source data
